After a quiet summer, biotech IPOs are attempting to notch up a few more deals in the autumn, but things remain tough, as AzurRX gets off its IPO, but at a…
The seed-stage fund Breakout Labs has added a new biotech, the skin disorder-focused Azitra, to its growing ranks of “hard science” companies.
Helsinn has set up a $50 million VC fund to place 10 to 15 bets on early-stage companies in the U.S., parts of Europe and Israel.
In the first quarter after Britain voted to leave the European Union, life sciences deals took a nosedive--and while Asia booked impressive surges in M&A…
Newron Pharmaceuticals has tapped investors for CHF 26.1 million to see it through to data readouts on a couple of key pipeline programs.
Philadelphia, PA-based Immunome has raised $5 million of a Series A round in April that it now said will hit $12.2 million.
Medicxi is putting up €10 million ($11 million) to help Kymo Therapeutics take kynurenine metabolism inhibitors through to clinical proof of concept.
Myovant Sciences and Ra Pharmaceuticals are lining up with IPOs for up to $172.5 million and $86.3 million, respectively.
Specialty pharma spinout Castle Creek Pharmaceuticals has raised its first institutional round of $48 million entirely from active biotech crossover investor…
Carrick Therapeutics has wrapped up a $95 million Series A to fuel its ambition to grow into Europe’s leading oncology company.